[New systemic therapies of psoriasis].
The metabolic-pathophysiological pathways are of prime importance when considering psoriasis therapy. Present-day concepts recognize that central growth hormone controls the metabolic route and that the peripheral pathway is under the control of several growth factors. Both the central and peripheral pathways induce pathological proliferation. A selection of six routine drugs, all with specific biochemical properties, induced part to total remission in about 75% of the 442 psoriasis patients.
Weber
G
G
Frey
H
H
Neugebauer
D
D
D000420:Albuterol / Q000627:therapeutic use; D001971:Bromocriptine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004221:Disulfiram / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D007665:Ketotifen / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy*; D013004:Somatostatin / Q000627:therapeutic use; D015016:Yohimbine / Q000627:therapeutic use
D015016:Yohimbine; D001971:Bromocriptine; D013004:Somatostatin; D000420:Albuterol; D004221:Disulfiram; D007665:Ketotifen
Neue systemische Therapien der Psoriasis.